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Patients Admitted With STEMI?” [ J Am Coll Cardiol 2013;61 Suppl A:A33, E134 in the online version]
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From Oxford University, Oxford, United Kingdom
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/
withdrawalpolicy).
This article has been retracted at the request of the author.
The prevalence of MVO was reduced in the adenosine-treated patients (45%) compared to 85% of control patients
(P¼0.0043). We found that the size of MVO in adenosine-treated patients was signiﬁcantly reduced (0.35g) compared to
0.91 g in the control group (P¼0.027). There was no statistically signiﬁcant difference in TIMI ﬂow and clinical outcomes
after primary PCI.
Excel software was used to calculate the p-values. On recalculation using a newer version of the programme, the values are
coming back different: Prevalence of MVO comparing adenosine to non-adenosine is now 0.15, therefore non-signiﬁcant.
Also the P-value for the mass of MVO in adenosine versus non-adenosine is 0.34, again non-signiﬁcant.
http://dx.doi.org/10.1016/j.jacc.2013.08.001Retraction notice to “Worsening of Pre-Existing Valvulopathy With A New Obesity Drug Lorcaserin, A Selective
5-Hydroxytryptamine 2C Receptor Agonist: A Meta-Analysis of Randomized Controlled Trials” [J Am Coll Cardiol
2013;61 Suppl A:A380, E1542 in the online version]
Hemang B. Panchal, Parthav Patel, Brijal Patel, Rakeshkumar Patel, Henry Philip
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/
withdrawalpolicy).
In currently published abstract, it was mentioned that the authors measured “change in degree of pre-existing valvulopathy”.
Actually, what they measured was “increase in valvular regurgitant grade from baseline” in a normal valve without any
evidence of pre-existing FDA-deﬁned valvulopathy. The studies included in their meta-analysis excluded patients with
FDA-deﬁned valvulopathy. Therefore, the outcome in their current abstract “increase in pre-existing AR” is actually
“increase in aortic regurgitant grade from baseline” in patients without pre-existing FDA-deﬁned aortic regurgitation.
Similarly, the outcome in their current abstract “increase in pre-existing MR” is actually “increase in mitral regurgitant grade
from baseline” in patients without pre-existing FDA-deﬁned mitral regurgitation. Study data and statistical analysis is
correct as it is. The results of their meta-analysis demonstrate that the increase in aortic regurgitant grade from baseline was
signiﬁcantly higher in patients on lorcaserin compared to placebo. The increase in mitral regurgitant grade from baseline
was not different between both groups. The interpretation of rest of the outcomes is correct as it is.
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